Related Experiment Video
Updated: Jun 2, 2025
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease and
Natalie Kreitzer1, Nancy M Albert2, Alpesh N Amin3
1Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Insights
Managing hyperkalemia, or high potassium levels, is crucial for patients with kidney disease and heart failure. New potassium binders offer effective treatment options while preserving essential medications.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Hyperkalemia (serum potassium >5.0 mEq/L) presents significant risks, including cardiac toxicity and muscle weakness.
- Prevalence increases in patients with chronic kidney disease (CKD), diabetes mellitus, and heart failure (HF), especially with certain medications.
- Impaired potassium regulation in CKD and acute kidney injury heightens risk, complicating management of chronic hyperkalemia.
Purpose of the Study:
- To describe optimal, multidisciplinary management strategies for hyperkalemia across clinical settings.
- To emphasize comprehensive care for patients with cardiovascular kidney metabolic syndrome.
- To outline methods for maintaining cardiovascular benefits of essential medications while managing potassium levels.
Main Methods:
- Convened a consensus panel of experts.
- Reviewed current management strategies for acute and chronic hyperkalemia.
- Focused on balancing essential therapies with potassium level control.
Main Results:
- Acute hyperkalemia management prioritizes cardiac protection via cellular stabilization and intracellular potassium shift.
- Chronic hyperkalemia management includes diet, diuretics, and potassium binders (e.g., patiromer, sodium zirconium cyclosilicate).
- Newer potassium binders demonstrate efficacy in lowering chronic hyperkalemia in CKD/HF patients, offering alternatives to older agents with adverse effects.
Conclusions:
- A multidisciplinary approach is essential for comprehensive hyperkalemia management.
- Newer potassium binders provide effective options for chronic hyperkalemia, particularly in CKD and HF populations.
- Strategies exist to safely manage potassium levels, enabling continued use of vital cardiovascular and renal medications.
Background:
Hyperkalemia, generally defined as serum potassium levels greater than 5.0 mEq/L, poses significant clinical risks, including cardiac toxicity and muscle weakness. Its prevalence and severity increase in patients with chronic kidney disease (CKD), diabetes mellitus, and heart failure (HF), particularly when compounded by medications like angiotensin converting inhibitors, angiotensin receptor blockers, and potassium sparing diuretics. Hyperkalemia arises from disruptions in potassium regulation involving intake, excretion, and intracellular-extracellular distribution. In CKD and acute kidney injury, these regulatory mechanisms are impaired, leading to heightened risk. The management of chronic hyperkalemia presents a challenge due to the necessity of balancing effective cardiovascular and renal therapies against the risk of elevated potassium levels.
Summary:
The emergency department management of acute hyperkalemia focuses on preventing cardiac complications through strategies that stabilize cellular membranes and shift potassium intracellularly. Chronic management often involves dietary interventions and pharmacological treatments. Pharmacological management of acute hyperkalemia includes diuretics, which enhance kaliuresis, and potassium binders such as patiromer and sodium zirconium cyclosilicate, which facilitate fecal excretion of potassium. While diuretics are commonly used, they carry risks of volume contraction and renal function deterioration. The newer potassium binders have shown efficacy in lowering chronically elevated potassium levels in CKD and HF patients, offering an alternative to diuretics and other older agents such as sodium polystyrene sulfonate, which has significant adverse effects and limited evidence for chronic use.
Key Messages:
We convened a consensus panel to describe the optimal management across multiple clinical settings when caring for patients with hyperkalemia. This consensus emphasizes a multidisciplinary approach to managing hyperkalemia, particularly in patients with cardiovascular kidney metabolic syndrome, to avoid fragmentation of care and ensure comprehensive treatment strategies. The primary goal of this manuscript is to describe strategies to maintain cardiovascular benefits of essential medications while effectively managing potassium levels.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: Diuretics
01:33Hormonal Regulation
01:26Heart Failure Drugs: Inotropic Agents
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...